SFU
LGND icon

Stonehage Fleming (UK)’s Ligand Pharmaceuticals LGND Stock Holding History

Stonehage Fleming (UK)’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-927
Closed -$36K – 328
2014
Q2 		$36K Sell
927
-610
-40% -$24.8K 0.01% 185
2014
Q1 		$64K Sell
1,537
-217
-12% -$9.04K 0.03% 222
2013
Q4 		$58K Buy
+1,754
New +$57.1K 0.02% 210

Other funds holding LGND

RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stonehage Fleming (UK)'s LGND Position: Q3 2014 in Review

Stonehage Fleming (UK) sold out of Ligand Pharmaceuticals (LGND) in Q3 2014, closing a stake of 927 shares — an estimated $36K sold.

Stonehage Fleming (UK) first reported a position in LGND in Q4 2013 and held it in 3 quarters. The position peaked at $64K in Q1 2014. 174 funds tracked by Wall St. Rank hold LGND as of Q3 2014.

  • Stonehage Fleming (UK) reported no remaining Ligand Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Stonehage Fleming (UK) sold 927 Ligand Pharmaceuticals shares in Q3 2014, an estimated $36K.
  • Stonehage Fleming (UK) first reported a position in Ligand Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • Stonehage Fleming (UK)'s Ligand Pharmaceuticals position peaked at $64K in Q1 2014.
  • 174 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2014.

Based on Stonehage Fleming (UK)'s 13F filing for Q3 2014, filed 11 Oct 2019.